Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma

Citation
M. Grande et al., Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma, PROSTATE, 45(4), 2000, pp. 299-303
Citations number
23
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
PROSTATE
ISSN journal
02704137 → ACNP
Volume
45
Issue
4
Year of publication
2000
Pages
299 - 303
Database
ISI
SICI code
0270-4137(200012)45:4<299:TCOTPA>2.0.ZU;2-K
Abstract
BACKGROUND. Following development of methods to quantitate biochemical mark ers in aspiration biopsies we showed that tissue concentration of prostate specific antigen (T-PSA) decreased with increasing malignancy while serum P SA increased. We also found that T-PSA predicts the clinical outcome better than earlier used prognostic markers. METHODS. In order to further study biochemical markers in prostatic cancer a membrane protein, tissue polypeptide antigen (TPA), which is a complex of polypeptide fragments of cytokeratins 8, 18, and 19, was quantitated in 42 patients with newly diagnosed carcinoma of the prostate. The samples had p reviously been analyzed for T-PSA. RESULTS. Correlation to TGM classification showed that higher malignancy is correlated to lower tissue TPA values. There is a significant positive cor relation (r(s) = 0.49, P < 0.01) between T-TPA and T-PSA. Pretreatment valu es of T-PSA, but not T-TPA, had association to time to progression or time to death. CONCLUSIONS. Increasing prostatic malignancy is correlated to decreasing va lues of TTPA. This indicates that the concentrations of membrane and secret ory proteins are changed in the same direction in tissue during cancer deve lopment. Tissue TPA seem to have no prognostic value in endocrine treatment of prostatic carcinoma. (C) 2000 Wiley-Liss, Inc.